NCT05831670View on ClinicalTrials.gov

An Early Phase 2 Clinical Study of KSP-0243

PHASE2CompletedINTERVENTIONAL
Enrollment

108

Participants

Timeline

Start Date

April 27, 2023

Primary Completion Date

October 18, 2024

Study Completion Date

October 18, 2024

Conditions
Colitis, Ulcerative
Interventions
DRUG

KSP-0243

Oral administration

DRUG

Placebo

Oral administration

Trial Locations (1)

Unknown

Research Site, Multiple Locations

Sponsors
All Listed Sponsors
lead

Kissei Pharmaceutical Co., Ltd.

INDUSTRY